Career officials at the Food and Drug Administration quietly reduced the number of children's deaths deemed likely connected to COVID-19 vaccines, changing their own assessments within days of an internal memo that triggered public scrutiny, according to internal agency emails released by Sen. Ron Johnson.
The emails, made public through a June 16 letter from Johnson to HHS, the CDC, and the FDA, show that the agency's Center for Biologics Evaluation and Research identified 10 pediatric deaths as probably or possibly connected to COVID-19 injections on November 22, 2025. By December 5, CBER officials had reclassified three of those deaths, downgrading them from "probably" or "possibly" vaccine-caused to "un-assessable" or "unlikely." A fourth case was shifted from "probably" to "possibly."
The children died in 2021 and 2022. The deaths did not come to public attention until late 2025.
On November 28, 2025, CBER Director Vinay Prasad sent what has been called the "Black Friday memo" to FDA staff, announcing the figure of 10 pediatric deaths and calling for higher standards for vaccines and "humility" from the agency. The memo leaked to reporters within hours. A media firestorm followed.
One week later, on December 5, the findings had changed. Meghna Alimchandani, deputy director of the FDA's Division of Pharmacovigilance, sent an internal email that day describing the review process in charged terms:
"This was a MONUMENTAL effort from all of us, to do a diligent review while being bombarded with media articles on the subject."
That language, "bombarded with media articles", raises an obvious question. Was the review shaped by scientific rigor, or by public pressure to soften the findings?
Johnson's letter frames the timeline bluntly. His office noted that although "what drove the decision to change these three cases remains to be seen, what is clear is that these officials appear to have determined that the seven cases warranted warning about the risks."
The emails reveal something else. The FDA's own Division of Pharmacovigilance recommended a label change for both the Moderna and Pfizer COVID vaccines to warn about "myocarditis with fatal outcomes." That change was never implemented.
The significance is hard to overstate. Federal regulators identified a potential lethal risk in a product administered to children, recommended that the warning be placed on the label, and then, nothing. No updated label. No public disclosure at the time. The deaths themselves stayed buried for years.
The pattern is familiar to anyone who has watched federal health agencies during and after the pandemic. Concerns raised internally get sanded down, deferred, or quietly shelved. The public hears reassurances. The bureaucracy protects itself. And the people who bear the consequences, in this case, families who lost children, are the last to know.
This is not the only instance of institutional accountability failures drawing congressional scrutiny in recent months.
Central to the reclassification is a forensic dispute over parvovirus, a common virus found in human tissue. James Gill, a forensic pathologist at the Yale School of Medicine, autopsied two teenage boys who died of myocardial injury days after receiving their second dose of the Pfizer vaccine. He co-authored a 2022 peer-reviewed study on the cases.
The CDC stored tissue slides from those autopsies, tested them, and reported finding clostridium septicum bacteria and parvovirus. The agency then published its own paper, claiming those findings muddied Gill's conclusions. FDA officials later cited the parvovirus results as a basis for downgrading the death assessments.
Gill rejects that reasoning outright. He told the Daily Caller News Foundation that parvovirus can be found in the tissues of approximately half the population, making it a weak basis for reclassification:
"It's like saying everyone with blue eyes must be excluded. It's kind of arbitrary I think. It's a red herring. Whether or not it was intentionally used as one, I don't know, but certainly that would be a case of looking at the pathology."
Gill said neither the FDA nor the CDC contacted him during their 2022 or 2025 reviews of the cases, despite the fact that he performed the autopsies and published the original findings. He described trying to engage the agencies and being shut out:
"I tried to engage them in that dialogue and they shut it down because they had already made up their mind that this was not a death due to the vaccine."
He also asked a question that federal health officials have yet to answer publicly: "Why would you not even want to discuss it with me professionally and sort it out?"
The refusal to consult the pathologist who actually examined the bodies, while using a common tissue finding to override his conclusions, is the kind of procedural shortcut that erodes public trust in federal science. It suggests the conclusion came first, and the justification followed.
Two former FDA officials, granted anonymity to discuss sensitive matters, offered assessments that reinforce the picture drawn by the emails. The first described the situation in stark terms:
"The career FDA scientists identified new safety information not on the label, that COVID-19 shots have caused deaths, that information should be added to the label, but has not been. During the heightened media scrutiny of this topic, scientists downcoded their initial impression of deaths. There is little desire for an accurate appraisal of COVID vaccine benefits and harms inside the agency."
A second former official raised the question of timing, why the 10 pediatric deaths, which occurred in 2021 and 2022, were not brought to public attention until the end of 2025:
"One wonders if there was internal pressure at the FDA during that time not to report these pediatric deaths in a timely manner."
That question hangs over the entire affair. The Biden administration spent years assuring the public that COVID vaccines were safe and effective for all age groups. If career FDA staff identified pediatric deaths linked to the shots but sat on the information, or were pressured to sit on it, the implications extend well beyond a labeling dispute.
The broader pattern of Biden-era policy failures surfacing under the current administration continues to grow.
Johnson's letter also targets the CDC's reported awarding of approximately $1.24 billion in new contracts to Pfizer, even as these safety questions remained unresolved. The senator wrote:
"The safety issues with the COVID-19 injections that the Subcommittee has uncovered so far should have raised serious concerns at HHS and CDC about the mRNA COVID-19 Injections. Instead, CDC's reported awarding of approximately $1.24 billion in new contracts to Pfizer for a vaccine linked to serious adverse events, including potentially the deaths of children, suggests CDC continues to fail to take its vaccine safety responsibilities seriously."
Neither the FDA, the CDC, nor Pfizer responded to requests for comment. Moderna also did not respond.
The silence is notable. When federal agencies face detailed, document-backed allegations about children's deaths, the public deserves more than a non-response.
Johnson's letter credits HHS Secretary Robert F. Kennedy Jr. with providing a "trove of millions of emails and other records" to the senator's Homeland Security and Government Affairs Select Subcommittee on Investigations. Johnson described Kennedy's leadership as taking steps "to address the failure of the Biden administration to take COVID-19 vaccine safety issues seriously."
The document release represents one of the most granular looks yet at how federal health agencies handled pediatric vaccine safety internally, and how those internal findings diverged from the public posture of confidence. The FDA's 2025 assessment classified one of Gill's autopsy cases as "probably" vaccine-related and another as "possibly" vaccine-related, even while citing the disputed parvovirus evidence.
Several key questions remain unanswered. At what level was the recommended label change blocked or declined? Did the FDA or CDC conduct any formal review of the pediatric deaths at the time they occurred in 2021 and 2022? What are the full terms of the CDC's $1.24 billion Pfizer contract? And what specific parvovirus test was used, and at what sensitivity threshold?
These are not rhetorical questions. They are the kind of factual gaps that congressional oversight exists to close. The political careers of former Biden administration officials may yet be shaped by how these answers land.
Strip away the bureaucratic language and the procedural hedging, and the core facts are these: FDA scientists identified 10 children who died after receiving COVID vaccines and assessed those deaths as probably or possibly connected to the shots. Within days of that finding becoming public, career staff reclassified three of those deaths downward. The agency's own pharmacovigilance division recommended a label warning about fatal myocarditis. That warning was never added. The deaths occurred years before they came to light. And the CDC, while these questions remained open, handed Pfizer another $1.24 billion.
A Yale pathologist who performed the autopsies says the agency used a common tissue finding, present in roughly half the population, as a pretext to dismiss his work. He says the FDA and CDC refused to engage with him professionally.
Former insiders say there was "little desire for an accurate appraisal" of vaccine harms inside the agency. The deputy director who oversaw the revised review described the process not in terms of scientific discovery but in terms of surviving a media onslaught.
The Biden family's various legal and political troubles have consumed headlines, but the institutional failures of the Biden-era federal health apparatus may prove far more consequential for ordinary Americans.
Parents trusted these agencies with their children's lives. The least those agencies owe them is honesty about how those children died, and why it took years and a change of administration to find out.
